Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>In this section: FDA approves a subdermal buprenorphine implant for maintenance treatment of opioid dependence; warns health professionals against using ketoconazole for the treatment of skin and nail fungal infection; investigates a possible link between canagliflozin and an increase in leg and foot amputations; advises against using fluoroquinolones for common infections; and green lights daclizumab for the treatment of relapsing multiple sclerosis.</p>

FDA Actions